Current and emerging therapies in multiple sclerosis: A systematic review

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 4, 2012, Pages 205-220

  Castro Borrero, Wanda ^a   Graves, Donna ^b   Frohman, Teresa C ^b   Flores, Angela Bates ^b   Hardeman, Paula ^b   Logan, Diana ^b   Orchard, Megan ^b   Greenberg, Benjamin ^b   Frohman, Elliot M ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

disease modifying therapies; emerging therapies; fingolimod; glatiramer acetate; interferon I; multiple sclerosis; natalizumab

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE; TYSABRIL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ALOPECIA; AMENORRHEA; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY; B LYMPHOCYTE; BACKACHE; BACTERIAL INFECTION; BRADYCARDIA; CARDIOTOXICITY; CHEST TIGHTNESS; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG DOSE TITRATION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FLU LIKE SYNDROME; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HAIR LOSS; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; INFLUENZA; INFUSION REACTION; INFUSION SITE REACTION; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; LEUKEMIA; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; LEUKOPENIA; LIPOATROPHY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE SPASM; MYCOSIS; NAUSEA; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RASH; RELAPSE; RESPIRATORY TRACT INFECTION; RETINA MACULA EDEMA; REVIEW; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SKIN CANCER; SKIN MANIFESTATION; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TH2 CELL; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREMOR; TUMOR LYSIS SYNDROME; URINARY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 84863580562     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612450936     Document Type: Review

References (79)

1. Achiron A. Gabbay U. Gilad R. Hassin-Baer R. Barak Y. Gornish M. et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398–402.
2. Achiron A. Kishner I. Sarova-Pinhas I. Raz H. Faibel M. Stern Y. et al. (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61: 1515–1520.
3. Achiron A. Rotstein Z. Noy S. Mashiach S. Dulitzky M. Achiron R. (1996) Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 243: 25–28.
4. Aharoni R. Teitelbaum D. Sela M. Arnon R. (1997) Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 94: 10821–10826.
5. Bar-Or A. Calabresi P.A. Arnold D. Markowitz C. Shafer S. Kasper L.H. et al. (2008) Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395–400.
6. Beck R.W. Cleary P.A. Trobe J.D. Kaufman D.I. Kupersmith M.J. Paty D.W. et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329: 1764–1769.
7. Berger J.R. (2010) Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 33: 969–983.
8. Bielekova B. Catalfamo M. Reichert-Scrivner S. Packer A. Cerna M. Waldmann T.A. et al. (2006) Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941–5946.
9. Biogen Idec (2011) Biogen Idec announces positive top-line results from the first phase III trial investigating oral BG-12 (dimethyl fumarate) in multiple sclerosis (press release). Weston, MA: Biogen Idec, 11 April 2011. Presented at 63rd annual meeting of the American Academy of Neurology, 9–16 April 2011, Honolulu, Hawaii.
10. Boster A. Ankeny D.P. Racke M.K. (2010) The potential role of B cell-targeted therapies in multiple sclerosis. Drugs 70: 2343–2356.
11. Casetta I. Iuliano G. Filippini G. (2009) Azathioprine for multiple sclerosis. J Neurol Neurosurg Psychiatry 80: 131–132; discussion 132.
12. Coelho R.P. Payne S.G. Bittman R. Spiegel S. Sato-Bigbee C. (2007) The immunomodulator FTY 720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 323: 626–635.
13. Cohen J.A. Barkhof F. Comi G. Hartung H.P. Khatri B.O. Montalban X. et al. for TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402–415.
14. Comi G. de Stefano N. Freedman M.S. et al. (2012 a) Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 11:33–41.
15. Comi G. Filippi M. Barkhof F. Durelli L. Edan G. Fernandez O. et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576–1582.
16. Comi G. Jeffery D. Kappos L. Montalban X. Boyko A. Rocca M.A. et al. (2012 b) Placebo controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366: 1000–1009.
17. Comi G. Martinelli V. Rodegher M. Moiola M. Bajenaru O. Carra A. et al. for PreCISe Study Group (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374:1503–1511.
18. Comi G. Pulizzi A. Rovaris M. Abramsky O. Arbiizu T. Boiko A. et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing–remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. The Lancet 371: 2085–2092.
19. Corboy J.R. Miravalle A. (2010) Emerging therapies for treatment of multiple sclerosis. J Inflamm Res 3: 53–60.
20. Cossburn M. Pace A.A. Jones J. Ali R. Ingram G. Baker K. et al. (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77: 573–579.
21. Di Piro J.T. Talbert R.L. Yee G.C. Matzke G.R. Wells B.G. Posey L.M. (2005) Pharmacotherapy, A Pathophysiologic Approach, 6th edition. New York: McGraw-Hill.
22. Elovaara I. Apostolski S. van Doorn P. Gilhus N.E. Hietaharju A. Honkaniemi J. et al. (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 15: 893–908.
23. Fazekas F. Deisenhammer F. Strasser-Fuchs S. Nahler G. Mamoli B. (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing–remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349: 589–593.
24. Fazekas F. Lublin F.D. Freedman M.S. Hartung H.P. Rieckmann P. Sorensen P.S. et al. (2008) Intravenous immunoglobulin in relapsing–remitting multiple sclerosis: a dose-finding trial. Neurology 71: 265–271.
25. Ford C. Goodman A.D. Johnson K. Kachuck N. Lindsey J.W. Lisak R. et al. (2010) Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 16: 342–350.
26. Foster C.A. Howard L.M. Schweitzer A. Persohn E. Hiestand P.C. Balatoni B. et al. (2007) Brain penetration of the oral immunomodulatory drug FTY 720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 323: 469–475.
27. Frohman E.M. Brannon K. Racke M.K. Hawker K. (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27: 80–83.
28. Frohman E.M. Cutter G. Remington G. Gao H. Rossman H. Weinstock-Guttman B. et al. (2010) A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing–remitting multiple sclerosis. Ther Adv Neurol Disord 3: 15–28.
29. Goodin D.S. Arnason B.G. Coyle P.K. Frohman E.M. Paty D.W. (2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61: 1332–1338.
30. Gorelik L. Lerner M. Bixler S. Crossman M. Schlain B. Simon K. et al. (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68: 295–303.
31. Goverman J.M. (2011) Immune tolerance in multiple sclerosis. Immunol Rev 214: 228–240.
32. Gray O. McDonnell G.V. Forbes R.B. (2004) Methotrexate for multiple sclerosis. Cochrane Database Syst Rev (2): CD003208.
33. Haas J. Hommes O.R. (2007) A dose comparison study of IVIG in postpartum relapsing–remitting multiple sclerosis. Mult Scler 13: 900–908.
34. Hartung H.P. Gonsette R. König N. Kwiecinski H. Guseo A. Morrissey S.P. et al.; Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomized, multicentre trial. Lancet 360: 2018–2025.
35. Hauser S.L. Waubant E. Arnold D.L. Vollmer T. Antel J. Fox R.J. et al. (2008) B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 358: 676–688.
36. Hawker K. O'Connor P. Freedman M.S. Calabresi P.A. Antel J. Simon J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471.
37. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.
38. Jacobs L.D. Beck R.W. Simon J.H. Kinkel R.P. Brownscheidle C.M. Murray T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898–904.
39. Jacobs L.D. Cookfair D.L. Rudick R.A. Herndon R.M. Richert J.R. Salazar A.M. et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39: 285–294.
40. Johnson K.P. (2010) The Remarkable Story of Copaxone. New York: Diamedica, pp. 70–73, 196–199.
41. Kappos L. Freedman M.S. Polman C.H. Edan G. Hartung H.P. Miller D.H. et al. (2009) Long term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8: 987–997.
42. Kappos L. Gold R. Miller D.H. Macmanus D.G. Havrdova E. Limmroth V. et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372: 1463–1472.
43. Kappos L. Li D. Calabresi P.A. O'Connor P. Bar-Or A. Barkhof F. et al. (2011) Ocrelizumab in relapsing–remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet 378: 1779–1787.
44. Kappos L. Lindberg R.L.P. (2007) Interferons in relapsing–remitting multiple sclerosis. In: Ed. Cohen J.A. Rudick R.A. (eds), Multiple Sclerosis Therapeutics, 3rd edition. London: Informa Healthcare, pp. 373–392.
45. Kappos L. Polman C.H. Freedman M.S. Edan G. Hartung H.P. Miller D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242–1249.
46. Kappos L. Radue E.W. O'Connor P. Polman C. Hohlfeld R. Calabresi P. et al. for the FREEDOMS Study Group (2010) A placebo controlled-trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387–401.
47. Kieseier B.C. (2011) The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 25: 491–502.
48. Korn T. Magnus T. Toyka K. Jung S. (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion. J Leukoc Biol 76: 950–960.
49. Lalive P.H. Neuhaus O. Benkhoucha M. Burger D. Hohlfeld R. Zamvil S.S. et al. (2011) Glatiramer acetate in the treatment of multiple sclerosis emerging concepts regarding its mechanism of action. CNS Drugs 25: 401–414.
50. La Mantia L. Mascoli N. Milanese C. (2007) Azathioprine. Safety profile in multiple sclerosis patients. Neurol Sci 28 (6): 299–303.
51. Lewanska M. Siger-Zajdel M. Selmaj K. (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9: 565–572.
52. Marriott J.J. Miyasaki J.M. Gronseth G. O'Connor P.W. (2010) Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74: 1463–1470.
53. Martinelli V. Radaelli M. Straffi L. Rodegher M. Comi G. (2009) Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 30(Suppl. 2): S167–S170.
54. McDonagh M. Dana T. Chan B.K.S. Thakurta S. Gibler A. (2007) Drug class review on disease-modifying drugs for multiple sclerosis: final report (internet). Portland, OR: Oregon Health & Science University. Available at: http://www.ncbi.nlm.nih.gov/books/NBK10578/ (last accessed July 2007).
55. Mikol D.D. Barkhof F. Chang P. Coyle P.K. Jeffery D.R. Schwid S.R. et al. (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7: 903–914.
56. Miron V.E. Jung C.G. Kim H.J. Kennedy T.E. Soliven B. Antel J.P. (2008) FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 63: 61–71.
57. Moharregh-Khiabani D. Linker R.A. Gold R. Stangel M. (2009) Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 7: 60–64.
58. O'Connor P. Filippi M. Arnason B. Comi G. Cook S. Goodin D. et al. (2009) Interferon beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes of New Dose) study. Lancet Neurol 8: 889–897.
59. O'Connor P. Wolinsky J. Confavreux C. Comi G. Kappos L. Olsson T.P. et al. for the TEMSO Trial Group (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365: 1293–1303.
60. Panitch H. Coles A.J. Compston P.A. Selmaj K.A. Lake S.L. Moran S. et al. for CAMMS 223 (2008) Alemtuzumab vs interferon B-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801.
61. Polman C.H. Barkhof F. Sandberg-Wollheim M. Linde A. Nordle O. Nederman T. et al. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis. Neurology 64: 987–991.
62. Polman C.H. Bertolotto A. Deisenhammer F. Giovannoni G. Hartung H.P. Hemmer B. et al. (2010) Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 9: 740–750.
63. Polman C.H. O'Connor PW. Havrdova E. Hutchinson M. Kappos L. Miller D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.
64. Prescribing information (2010) RITUXAN® (rituximab). San Francisco: Genentech.
65. Prevention of Relapses and Disability by Interferon beta 1-a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group and Ebers, G.C. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing / remitting multiple sclerosis. Lancet 352: 1498–1504.
66. Product information: Cellcept (2009) Nutley, NJ: Roche Laboratories.
67. Product information: methotrexate oral tablet (2000) Columbus, OH: Roxane Laboratories.
68. Product information: methotrexate injections (2005) USP, methotrexate sodium. Paramus, NJ: Mayne Pharma.
69. Ransohoff R.M. (2007) Natalizumab for multiple sclerosis. N Engl J Med 356: 2622–2629.
70. Ravnborg M. Sorensen P.S. Andersson M. Celius E.G. Jongen P.J. Elovaara I. et al. (2010) Methylprednisolone in combination with interferon beta-1a for relapsing remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurology 9: 672–680.
71. Rudick R.A. Stuart W.H. Calabresi P.A. Confavreux C. Galetta S.L. Radue E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354: 911–923.
72. Schimrigk S. Brune N. Hellwig K. Lukas C. Bellenberg B. Rieks M. et al. (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13 (6): 604-610.
73. Sorensen P.S. Mellgren S.I. Svenningsson A. Elovaara I. Frederiksen J.L. Beiske A.G. et al. (2009) NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing–remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 8: 519–529.
74. Sorensen P.S. Bertolotto A. Edan G. Giovannoni G. Gold R. Havrdova E. et al. (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumb. Mult Scler 18: 143–152.
75. Thöne J. Gold R. (2011) Laquinimod: a promising oral medication for the treatment of relapsing–remitting multiple sclerosis. Expert Opin Drug Metab Toxicol 7: 365–370.
76. Vollmer T.L. Sorensen P.S. Arnold D.L. MS-LAQ-302 Benefit Risk Assessment of Avonex and Laquinimod (BRAVO) Study Group (2011) A placebo-controlled and active comparator phase iii trial of oral laquinimod in relapsing–remitting multiple sclerosis patients, Bittman, R., Spiegel, S. and Sato-Bigbee, C. (NCT00605215). Abstract 148. Presented at: 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), October 2011.
77. Wierinckx A. Breve J. Mercier D. Schultzberg M. Drukarch B. van Dam A.M. (2005) Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J Neuroimmunol 166: 132–143.
78. Wynn D. Kaufman M. Montalban X. Vollmer T. Simon J. Elkins J. et al. (2011) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9: 381–390.
79. Zivadinov R. Rudick R.A. de Masi R. Nasuelli D. Ukmar M. Pozzi-Mucelli R.S. et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing–remitting MS. Neurology 57: 1239–1247.